Mymetics Corp (MYMX)

[bow-tie]

Study investigates the production of a virosome-based COVID-19 vaccine candidate

Implications
This research shows that an insect cells-baculovirus expression vector system can be used to create high-quality SARS-CoV-2 S protein for the implementation in a virosome-based COVID-19 vaccine candidate. The authors claim that the bioprocessing engineering approach used here permitted them to produce 4 mg/L of full-length S protein, which is the greatest value achieved to date utilizing insect cells.

Furthermore, the S protein produced from insect Sf-9 cells showed glycan processing identical to mammalian cells and mid-term storage durability. Moreover, even after a month of storage at 4 °C, the S protein on the exterior of the virosomes had the capacity to bind to the ACE2 receptor and was recognized by a wide range of neutralizing antibodies. Immunogenicity and safety-toxicology investigations in appropriate animal models should be carried out to verify these particles as COVID-19 vaccine candidates.
https://www.news-medical.net/news/20220418/Study-investigates-the-production-of-a-virosome-based-COVID-19-vaccine-candidate.aspx